In HIV patients with belly fat who responded to tesamorelin, denser visceral fat (on CT scans) was associated with less visceral fat area, showing that fat quality and quantity are related.

When HIV patients with belly fat responded to tesamorelin, thicker visceral fat (as seen on CT scans) was linked to higher levels of adiponectin, a hormone that helps regulate metabolism.

For HIV patients with belly fat who responded to tesamorelin, denser subcutaneous fat (on CT scans) was linked to less subcutaneous fat area, showing that fat quality and quantity are related.

When HIV patients on tesamorelin had denser belly fat, their bodies also produced more adiponectin, a hormone that helps regulate metabolism, showing a link between fat quality and metabolic health.

In HIV patients with belly fat who responded to tesamorelin, thicker subcutaneous fat (on CT scans) was linked to higher adiponectin levels, which is beneficial for metabolic health.

Only HIV patients whose belly fat shrinks by at least 8% after taking this drug also get healthier-looking fat on scans — others don’t benefit in this way.